Main Menu

Therapeutics

The Institute of Cancer Research currently has a number of partnering and licensing opportunities and any member of the Enterprise Unit would be pleased to review these with potential commercial collaborators. 

Counting pills returned from a clinical trial (Jan Chlebik for the ICR, 2014)

Lysyl Oxidase

Wellcome Trust collaboration and licensing opportunity.

Principal Scientist: Professor Caroline Springer

Lysyl oxidase (LOX) is an extracellular enzyme responsible for crosslinking of collagen and elastin. LOX expression is regulated by hypoxia inducible factors (HIFs) and LOX is upregulated in hypoxic tumours. Secreted LOX leads to invasion and metastases and hence inhibitors of LOX should prevent tumour progression and metastases.

For more information contact Angela Kukula or download the PDF flyer.

Contacts

Jonathan Beech Business Development Manager
Angela Kukula Director of Enterprise

Connections newsletter

Sign up to our new quarterly newsletter for updates on our Enterprise Unit and news about working with industry.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.